OncoMatch/Clinical Trials/NCT07638371
FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers
Is NCT07638371 recruiting? Yes, currently enrolling (Jul 2026). This Phase 1 trial studies MSK-TCR5 for solid tumor.
Treatment: MSK-TCR5 — The purpose of this study is to test the safety of MSK-TCR5 in participants with advance solid tumor cancer that has a KRAS, HRAS, or NRAS G12D mutation.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Biomarker criteria
Required: KRAS g12d
Positive for RAS G12D mutation
Required: HLA-A a*11:01
Positive for ... HLA-A*11:01 allele
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — advanced solid tumor
after at least 1 line of systemic standard of care (SOC) treatment regimen
Cannot have received: allogeneic stem cell transplantation
Previous allogeneic stem cell transplantation or prior organ transplantation
Cannot have received: organ transplantation
Previous allogeneic stem cell transplantation or prior organ transplantation
Lab requirements
Blood counts
ANC ≥1000/mm3 without G-CSF support; Platelets ≥75,000/mm3 without transfusion within 7 days; Hemoglobin ≥8.0 g/dL (transfusion permitted within 7 days)
Kidney function
CrCl ≥50 mL/min by Cockcroft-Gualt equation
Liver function
AST, ALT, and ALP ≤ 3x ULN, or ≤ 5x ULN if liver or bone metastases present; Total bilirubin ≤ 1.5x ULN or ≤ 3x ULN in the presence of documented Gilbert's Syndrome
Cardiac function
No significant cardiovascular abnormalities as defined by: uncontrolled congestive heart failure or hypertension, clinically significant hypotension, symptomatic coronary artery disease, or EF < 50%
Adequate organ and bone marrow function based on the following laboratory values: ANC ≥1000/mm3 without G-CSF support; Platelets ≥75,000/mm3 without transfusion within 7 days; Hemoglobin ≥8.0 g/dL (transfusion permitted within 7 days); AST, ALT, and ALP ≤ 3x ULN, or ≤ 5x ULN if liver or bone metastases present; Total bilirubin ≤ 1.5x ULN or ≤ 3x ULN in the presence of documented Gilbert's Syndrome; CrCl ≥50 mL/min by Cockcroft-Gualt equation. Significant cardiovascular abnormalities as defined by: uncontrolled congestive heart failure or hypertension, clinically significant hypotension, symptomatic coronary artery disease, or EF < 50% [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07638371 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic stem cell transplantation, organ transplantation disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS g12d is a required biomarker for enrollment.
Does this trial require HLA-A?
Yes, HLA-A a*11:01 is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify